malaria

The Journal of Experimental Medicine published Phase 2 results last week showing that Novartis’ enzyme-blocking cancer drug imatinib cleared malaria parasites from 100% of treated adult Vietnamese men in three days when used in combination with standard of care (piperaquine plus dihydroartemisinin).

In contrast, 33% of trial participants who received only standard of care without the imatinib supplement experienced delayed parasite clearance rates—a precursor to and an indicator of…

Mentions:

The New England Journal of Medicine published Phase 3 results last week showing that seasonal vaccination with GSK’s RTS,S/AS01e malaria vaccine in combination with chemoprevention was superior to either intervention alone in children ages 5-17 months.

The trial—conducted in Burkina Faso and Mali—tested a regimen of three doses of the vaccine (followed by two annual boosters just before the peak of the malaria transmission season) and four courses of sulfadoxine-pyrimethamine and…

Mentions:

The New England Journal of Medicine published Phase 1 results Wednesday from a small trial showing that a single infusion of an investigational antimalarial monoclonal antibody (CIS43LS) prevented infection for up to nine months in malaria-naïve adults exposed to P. falciparum.

The drug—developed by the U.S. National Institute of Allergy and Infectious Diseases—is also being tested in a larger Phase 2 trial in Mali to evaluate its ability to prevent infection in adults during a six-…

Mentions:

In a three-way financing agreement announced Wednesday, Gavi will fund GSK’s continued manufacturing of the antigen for the British pharma company’s RTS,S/AS01e malaria vaccine, pending a WHO decision expected later this year on whether to recommend the shot for broader use.

If WHO does endorse and Gavi’s board approves a malaria vaccination program, GSK would then credit the value of the Gavi-funded costs toward procurement of finished doses, according to a joint press release.…

Germany’s BioNTech announced Monday that it is “evaluating sustainable mRNA vaccine production capacities in Africa” for a candidate malaria shot and other vaccines.

The company said in a press release it would select promising candidates for clinical development from “multiple vaccines featuring known [m]alaria targets” (such as the circumsporozoite protein) while also evaluating new antigens. First trials are planned for year-end 2022.

In the same press release, BioNTech said…

The string of good news for Sanaria’s PfSPZ-CVac malaria vaccine candidate continued Wednesday with promising Phase 1 data based on human challenges.

The research, published in the journal Nature, found that two versions of the chemoprophylaxis-attenuated whole-organism vaccine regimen protected volunteers three months following dosing, according to a press release from the U.S. National Institutes of Health, which helped conduct the trial: seven out of eight volunteers who received…

Mentions:

Promising mRNA vaccines made news again last week as the U.S. Walter Reed Army Institute of Research announced that its investigational shot against P. falciparum malaria achieved “high levels of protection” in mice. NPJ Vaccines published the study on the jab (PfCSP mRNA-LNP), co-developed with Acuitas Therapeutics and other collaborators.

In other malaria news, Life Science Alliance published details last week on a method developed by Imperial College London researchers for isolating…

The Lancet Infectious Diseases published study results on Monday showing that the efficacy of the non-artemisinin-based triple-drug combination arterolane-piperaquine-mefloquine was noninferior to both arterolane-piperaquine and the artemisinin-based combination artemether-lumefantrine for treating uncomplicated P. falciparum malaria.

The study—funded by the Gates Foundation and Wellcome, among others—said the triple combination could “potentially be used to prevent or delay the…

Mentions:

A human challenge trial of Sanaria’s PfSPZ-CVac malaria vaccine candidate left 10 out of 13 subjects “completely immune,” the German Center for Infection Research (DZIF) announced Tuesday.

The chemoprophylaxis-attenuated whole-organism vaccine regimen from Maryland-based Sanaria involves the simultaneous administration of P. falciparum parasites and an antimalarial drug. The research also showed that vaccination with parasites from Africa could also protect against “genetically diverse…

Researchers from Oxford University’s Jenner Institute published data last week showing that their candidate prophylactic malaria vaccine achieved 77% efficacy over 12 months of follow-up in Phase 2b trials in children age 5-17 months. The study, in Burkina Faso, started in 2019.

The adjuvanted R21/Matrix-M shot—the first to achieve WHO’s goal of at least 75% efficacy—showed a favorable safety profile and was well-tolerated, leading the researchers to extend the trial with a booster (…